Teva and Polpharma Biologics sign global Ocrevus® Biosimilar licensing deal
Polpharma Biologics and PSI CRO collaborate on Phase 1 study
Latest news
Teva and Polpharma Biologics sign global Ocrevus® Biosimilar licensing deal
Polpharma Biologics and PSI CRO collaborate on Phase 1 study
Polpharma Biologics and Tuteur sign a licensing deal for a biosimilar for autoimmune diseases
Bioeq and Zydus partner for NUFYMCO®, a Lucentis® biosimilar
Polpharma and Libbs sign licensing deal for a biosimilar for autoimmune diseases
Polpharma Biologics confirms U.S. launch of Tyruko®, the first and only biosimilar for Multiple Sclerosis
Polpharma Biologics launches Europe's first pre-filled syringe of a ranibizumab biosimilar
Polpharma Biologics is splitting its operations into two independent companies
Polpharma and MS Pharma sign biosimilar agreements
Polpharma Biologics and Fresenius Kabi sign agreement for PB016
Lucentis® biosimilar Ranivisio® approved for retinopathies in Brazil
Polpharma Biologics' biosimilar shows comparability to Entyvio®
Polpharma Biologics announces Europe's first biosimilar for multiple sclerosis – Tyruko®
Polpharma Biologics announces FDA approval of Tyruko®, a biosimilar to Tysabri®
A unique MS biosimilar, natalizumab, gets positive CHMP opinion
European Commission approves FYB201, a Lucentis biosimilar
FDA approves FYB201/CIMERLI™, the first biosimilar interchangeable with Lucentis
FDA acceptance of natalizumab, a proposed biosimilar to Tysabri®
EMA accepts marketing authorization for biosimilar Natalizumab
Bioeq and MS Pharma sign exclusive Ranibizumab agreement in MENA
Polpharma Biologics Group's Bioeq submitted a BLA for biosimilar Ranibizumab to the FDA
Polpharma Biologics and Bioeq have a commercialization deal for biosimilar Ranibizumab
Polpharma Biologics announces global deal for biosimilar natalizumab, a key MS medicine
Teva and Polpharma Biologics sign global Ocrevus® Biosimilar licensing deal
Polpharma Biologics and PSI CRO collaborate on Phase 1 study
Polpharma Biologics and Tuteur sign a licensing deal for a biosimilar for autoimmune diseases
Bioeq and Zydus partner for NUFYMCO®, a Lucentis® biosimilar
Polpharma and Libbs sign licensing deal for a biosimilar for autoimmune diseases
Polpharma Biologics confirms U.S. launch of Tyruko®, the first and only biosimilar for Multiple Sclerosis
Polpharma Biologics launches Europe's first pre-filled syringe of a ranibizumab biosimilar
Polpharma Biologics is splitting its operations into two independent companies
Polpharma and MS Pharma sign biosimilar agreements
Polpharma Biologics and Fresenius Kabi sign agreement for PB016
Lucentis® biosimilar Ranivisio® approved for retinopathies in Brazil
Polpharma Biologics' biosimilar shows comparability to Entyvio®
Polpharma Biologics announces Europe's first biosimilar for multiple sclerosis – Tyruko®
Polpharma Biologics announces FDA approval of Tyruko®, a biosimilar to Tysabri®
A unique MS biosimilar, natalizumab, gets positive CHMP opinion
European Commission approves FYB201, a Lucentis biosimilar
FDA approves FYB201/CIMERLI™, the first biosimilar interchangeable with Lucentis
FDA acceptance of natalizumab, a proposed biosimilar to Tysabri®
EMA accepts marketing authorization for biosimilar Natalizumab
Bioeq and MS Pharma sign exclusive Ranibizumab agreement in MENA
Polpharma Biologics Group's Bioeq submitted a BLA for biosimilar Ranibizumab to the FDA
Polpharma Biologics and Bioeq have a commercialization deal for biosimilar Ranibizumab
Polpharma Biologics announces global deal for biosimilar natalizumab, a key MS medicine
Teva and Polpharma Biologics sign global Ocrevus® Biosimilar licensing deal
Polpharma Biologics and Tuteur sign a licensing deal for a biosimilar for autoimmune diseases
Bioeq and Zydus partner for NUFYMCO®, a Lucentis® biosimilar
Polpharma and Libbs sign licensing deal for a biosimilar for autoimmune diseases
Polpharma and MS Pharma sign biosimilar agreements
Polpharma Biologics and Fresenius Kabi sign agreement for PB016
Bioeq and MS Pharma sign exclusive Ranibizumab agreement in MENA
Polpharma Biologics and Bioeq have a commercialization deal for biosimilar Ranibizumab
Polpharma Biologics announces global deal for biosimilar natalizumab, a key MS medicine
Polpharma Biologics confirms U.S. launch of Tyruko®, the first and only biosimilar for Multiple Sclerosis
Polpharma Biologics launches Europe's first pre-filled syringe of a ranibizumab biosimilar
Polpharma Biologics announces Europe's first biosimilar for multiple sclerosis – Tyruko®
Lucentis® biosimilar Ranivisio® approved for retinopathies in Brazil
Polpharma Biologics' biosimilar shows comparability to Entyvio®
Polpharma Biologics announces FDA approval of Tyruko®, a biosimilar to Tysabri®
A unique MS biosimilar, natalizumab, gets positive CHMP opinion
European Commission approves FYB201, a Lucentis biosimilar
FDA approves FYB201/CIMERLI™, the first biosimilar interchangeable with Lucentis
FDA acceptance of natalizumab, a proposed biosimilar to Tysabri®
EMA accepts marketing authorization for biosimilar Natalizumab
Polpharma Biologics Group's Bioeq submitted a BLA for biosimilar Ranibizumab to the FDA
